Gilead Sciences, Inc. (GILD) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
GILD price how computed
Forward Fair Value verdict
OvervaluedGILD is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $151.17
- Sector
- Healthcare
- 12-month range
- $117.88–$157.37
- Market cap
- $187B
- From 52-week high
- -3.9%
- Shares outstanding
- 1.24B
- Rank in Healthcare by discount to fair value
- #85 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Gilead Sciences, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes medicines for diseases including HIV, hepatitis B and C, and certain cancers. The company operates globally with research, manufacturing, and distribution facilities across multiple continents to serve patients worldwide.
GILD currently ranks #85 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $187B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $30.5B
- Net margin
- -10.6%
- EPS (TTM)
- $-0.39
- Gross margin
- 79.8%
- Debt / equity
- 2.22
- Revenue growth (3-yr avg)
- 3.6%
- Shares outstanding
- 1.24B
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 60 · neutral
- 50-day average
- $146.84
- 200-day average
- $138.03
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $3.25 per share (4 payments)
- Yield on last price
- 2.15%
- Consecutive years of increases
- 10
- Last ex-dividend date
- 2026-09-15
- Last payment date
- 2026-09-29
Earnings how computed
- Next earnings report
- 2026-10-29
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+4.5%)
2026-03 ▲ beat (+6.3%)
2025-12 ▲ beat (+2.8%)
2025-09 ▲ beat (+15.4%)
2025-06 ▲ beat (+3.1%)
2025-03 ▲ beat (+1.7%)
2024-12 ▲ beat (+11.7%)
2024-09 ▲ beat (+30.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 22 buy · 5 hold · 1 sell (28 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $160
- Target vs last price
- +5.8%
What our data shows for GILD
- Our model validated 16 trailing price-to-earnings windows for GILD, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $117.88–$157.37.
- The 14-day relative strength index sits at a neutral 60.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for GILD
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent GILD news
TickrTrends' derived news-sentiment signal for GILD is currently leaning positive, computed from recent coverage.
- Gilead Sciences (GILD) Reports Promising Mid-Stage Trial Results for Emvistegrast in Ulcerative Colitis (gurufocus.com, 2026-10-19)
TickrTrends take: Gilead Sciences released positive interim data for emvistegrast, a potential treatment for ulcerative colitis, which could expand the company's pipeline beyond its current revenue base. Given TickrTrends' current assessment that GILD trades at overvalued levels within the Healthcare sector, investors should monitor whether this development justifies the existing valuation or if it represents genuine value creation relative to the company's current market price. The progression of this mid-stage program and its commercial potential will be key metrics for reassessing whether the stock's premium valuation reflects realistic earnings prospects. - Gilead Sciences (GILD) Insider Johanna Mercier Sells 3,000 Shares (gurufocus.com, 2026-10-16)
TickrTrends take: Insider selling activity at Gilead Sciences occurs against a backdrop where TickrTrends' analysis indicates the stock is trading at overvalued levels within the Healthcare sector. When company insiders reduce their holdings, it may signal concerns about near-term prospects or valuation, which could reinforce existing bearish technical signals for investors already skeptical of current price levels. A valuation-focused reader should monitor whether additional insider transactions follow this sale, as patterns of selling can sometimes precede downward price pressure in stocks already identified as overpriced. - Gilead Sciences (GILD) CFO Andrew Dickinson Sells 3,000 Shares (gurufocus.com, 2026-10-16)
TickrTrends take: Gilead Sciences trades at a valuation that TickrTrends currently classifies as overvalued, making insider selling activity particularly relevant for investors monitoring the stock's fundamental worth. The CFO's sale of 3,000 shares adds to the data point that company insiders may view current pricing as elevated relative to the company's underlying value. For valuation-conscious observers, such insider transactions warrant attention when the broader technical assessment already signals price may not align with intrinsic worth in the Healthcare sector.
More GILD news
- Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (zacks.com, 2026-10-15)
- Is Gilead Sciences Inc (GILD) Overvalued After 3.8% Rally? GF Value Says Overvalued (gurufocus.com, 2026-10-14)
- Stock Market Movers: Best and Worst Performers of 14 October 2026 (insidermonkey.com, 2026-10-14)
- Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (manilatimes.net, 2026-10-12)
- Can Gilead (GILD) Stock Continue Rising in 2027? (insidermonkey.com, 2026-10-12)
- Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive? (insidermonkey.com, 2026-10-11)
What people are saying
Follow the GILD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is GILD stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), GILD is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is GILD's TickrTrends verdict?
GILD's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does GILD compare to other Healthcare stocks?
GILD ranks #85 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is GILD overbought or oversold?
GILD's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does GILD pay a dividend?
Yes. GILD paid $3.25 per share over the last twelve months (4 payments), a 2.15% yield on TickrTrends' last price, and has raised the annual total for 10 consecutive years. The last ex-dividend date was 2026-09-15.
When does GILD report earnings next?
GILD's next earnings report is scheduled for 2026-10-29, per the published earnings calendar.
Does GILD usually beat earnings estimates?
Over its last 8 reported quarters GILD beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about GILD?
Of 28 analysts covering GILD, 22 rate it a buy, 5 a hold and 1 a sell - buy-leaning, with a consensus price target of $160 (+5.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
GILD vs ALVO · GILD vs AMGN · GILD vs AZTA · GILD vs CRL · GILD vs DGX